Oxidative Stress and Heart Risk in People with Rheumatoid Arthritis
Official title: Oxidative Stress and Cardiovascular Comorbidity in Patients With Rheumatoid Arthritis
Run by University of La Laguna · NCT07760662 · Data updated 2026-11-12
This study tests whether certain markers of oxidative stress in people with rheumatoid arthritis are linked to subclinical atherosclerosis and arterial stiffness, which could relate to future heart disease risk.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | University of La Laguna Academic / other |
| Drugs / interventions | prednisone |
| Locations | 1 site (Santa Cruz de Tenerife, Canary Islands) |
| Status | Recruiting |
| Started | January 1, 2024 |
| Main results expected | August 1, 2026 |
| Study ends | December 2026 |
| Registry record updated | August 12, 2026 |
| Trial ID | NCT07760662 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 to under 70 with rheumatoid arthritis, on stable DMARD therapy (including biologics) and (if on prednisone) 10 mg/day or less for at least one month.
✕Probably not a fit
Patients not fitting the inclusion criteria or with exclusion conditions (e.g., non-RA autoimmune diseases or severe functional disability) may not derive any direct cardiovascular benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational cross-sectional study will enroll adults with rheumatoid arthritis to examine whether serum oxidative stress markers—malondialdehyde, superoxide dismutase, and glutathione peroxidase—are associated with subclinical atherosclerosis and carotid arterial stiffness. The research will also explore how these molecules relate to cardiovascular risk factors such as inflammatory lipid changes, insulin resistance, and beta-cell function. The investigation aims to better understand how oxidative stress may contribute to cardiovascular disease in RA. No interventional treatment is being tested, and the study will describe associations rather than causality. The lead site is Hospital Universitario de Canarias in Tenerife, with the University of La Laguna as sponsor.
Why it matters
Potential benefit: If associations are found, this work could help identify oxidative stress markers that signal higher cardiovascular risk in RA patients.
How similar studies have gone: Previous research has linked oxidative stress and cardiovascular risk in RA, but this specific cross-sectional evaluation of selective biomarkers and subclinical atherosclerosis in RA is a relatively novel synthesis.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Men or women who are not pregnant or breastfeeding. * Age 18 years or older and younger than 70 years. * Treatment with any disease-modifying antirheumatic drug, including biologic therapies. * For patients receiving oral corticosteroids, a prednisone dose of 10 mg or less that has remained stable for at least one month before study inclusion. * Ability and willingness to provide written informed consent. Exclusion Criteria: * Autoimmune rheumatic disease other than RA, including systemic lupus erythematosus, mixed connective tissue disease, systemic sclerosis, or polymyositis. Sjögren syndrome associated with RA will not be an exclusion criterion. * Functional class IV RA with complete or substantial disability, including confinement to bed or wheelchair that prevents personal self-care. * History or current presence of inflammatory joint disease other than RA, such as gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy, or Lyme disease. * Estimated glomerular filtration rate below 60 mL/min/1.73 m² or active renal disease. * Pregnancy or breastfeeding. * Evidence of severe uncontrolled concomitant cardiovascular, neurological, pulmonary (including obstructive lung disease), renal, hepatic, endocrine (including diabetes mellitus), or gastrointestinal disease, or any condition considered by the investigator likely to alter the lipid profile. * Body weight greater than 150 kg. * History of alcoholism, drug abuse, or substance misuse within six months before the screening visit. * Statin use will not be an exclusion criterion.
Where it's running
-
Hospital Universitario de Canarias
Santa Cruz de Tenerife, Canary Islands, Spain Recruiting
Study contacts
- Study coordinator: Ivan Ferraz, MD
- Email: iferraza@ull.edu.es
- Phone: +34647868518
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Diabetes, Dementia, and Oxidative Stress: A look at Nox2-related markers
This study tests whether oxidative stress linked to Nox2 is related to dementia risk in adults with type 2 diabetes.
-
Air filters at home to see if breathing cleaner air helps heart health in obesity
This study tests whether portable air filtration systems can improve cardiovascular risk factors in adults with obesity and high blood pressure.
-
Heart Rate Variability and Rheumatoid Arthritis: What HRV Looks Like with RA
This study checks whether continuous HRV data from an Oura ring can reflect RA disease activity in adults with RA.
-
Bringing preventive cardiovascular care to Indigenous and remote communities
This project tests a mobile health unit to screen and provide culturally safe cardiovascular and metabolic care for Indigenous and remote communities in Canada.
-
Opioid-Free vs Opioid-Based Anesthesia for Thyroid Surgery
This study tests whether a non-opioid anesthesia approach can match or improve outcomes for adults undergoing thyroidectomy.
-
Training to reduce oxidative stress in knee OA
A six-week program compares supervised knee-strengthening training with a daily 6,000-step walking plan to see if it improves pain, function, and blood markers of cellular stress in people with knee osteoarthritis.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.